UPADACITINIB and COVID 19

Overview

COVID 19 is the #4 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 3,131 FDA adverse event reports linking UPADACITINIB to COVID 19. This represents approximately 2.8% of all 110,317 adverse event reports for this drug.

UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COVID 19 is a less commonly reported adverse event for UPADACITINIB, but still significant enough to appear in the safety profile.

Other Side Effects of UPADACITINIB

In addition to covid 19, the following adverse reactions have been reported for UPADACITINIB:

• PAIN — 4,942 reports
• ARTHRALGIA — 4,342 reports
• DRUG INEFFECTIVE — 4,175 reports
• RHEUMATOID ARTHRITIS — 3,037 reports
• PAIN IN EXTREMITY — 2,575 reports
• FATIGUE — 2,433 reports
• FALL — 2,255 reports
• SURGERY — 2,204 reports
• HEADACHE — 1,792 reports
• THERAPY INTERRUPTED — 1,783 reports

Other Drugs Associated with COVID 19

The following drugs have also been linked to covid 19 in FDA adverse event reports:

Does UPADACITINIB cause COVID 19?

COVID 19 has been reported as an adverse event in 3,131 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COVID 19 with UPADACITINIB?

COVID 19 accounts for approximately 2.8% of all adverse event reports for UPADACITINIB, making it a notable side effect.

What should I do if I experience COVID 19 while taking UPADACITINIB?

If you experience covid 19 while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages